Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): Results from the international SCHOLAR-1 study.

• DOI: 10.1200/jco.2016.34.15_suppl.7516
• Publication Date: 2018-09-06T16:34:56Z
• Authors: Michael Crump; Sattva Swarup Nee...; Umar Farooq; Eric Van Den Neste; John Kuruvilla; Mohamed Amin Ahmed; Brian K. Link; Annette E. Hay; James Robert Cerhan; Liting Zhu; Sami Boussetta; Lei Feng; Matthew John Maurer; Lynn Navale; Jeffrey S. Wiezorek; William Y. Go; Christian Gisselb...
• Keywords: 0301 basic medicine; 0303 health sciences; 03 medical and health sciences; 3. Good health

7516Background: Patients with relapsed/refractory DLBCL have heterogeneous outcomes to subsequent therapy. The subgroup of these patients with refractory disease (r-DLBCL) have a worse prognosis. A multi-cohort study, SCHOLAR-1 (Retrospective Non-Hodgkin Lymphoma Research) was performed to evaluate outcomes for patients with r-DLBCL and serve as a benchmark for future clinical trials in this population. Methods: Eligible subjects had r-DLBCL defined as progressive disease (PD) or stable disease (SD) as best response to chemotherapy (duration of SD <12 mos and at least 4 cycles of first-line or 2 cycles of later line therapy) or relapse ≤12 mos of ASCT. Patients must have received an anti-CD20 monoclonal antibody (unless CD20-) and an anthracycline as one of their prior regimens. Data from 2 phase 3 studies (LYSARC-CORAL and Canadian Cancer Trials Group-LY.12), and 2 observational cohorts (MD Anderson Cancer Center (MDACC), and Mayo Clinic / University of Iowa (MC/IA) Specialized Program of Research Excell...